Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

PMVP

PMV Pharmaceuticals (PMVP)

PMV Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:PMVP
FechaHoraFuenteTítuloSímboloCompañía
10/06/202415:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PMVPPMV Pharmaceuticals Inc
07/06/202407:32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PMVPPMV Pharmaceuticals Inc
30/05/202406:00GlobeNewswire Inc.PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in JuneNASDAQ:PMVPPMV Pharmaceuticals Inc
29/05/202406:00Business WireFoundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C ReactivatorNASDAQ:PMVPPMV Pharmaceuticals Inc
09/05/202407:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PMVPPMV Pharmaceuticals Inc
09/05/202407:00GlobeNewswire Inc.PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate HighlightsNASDAQ:PMVPPMV Pharmaceuticals Inc
27/03/202407:00GlobeNewswire Inc.PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid TumorsNASDAQ:PMVPPMV Pharmaceuticals Inc
18/03/202415:01GlobeNewswire Inc.PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s CancerNASDAQ:PMVPPMV Pharmaceuticals Inc
29/02/202415:01GlobeNewswire Inc.PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate HighlightsNASDAQ:PMVPPMV Pharmaceuticals Inc
26/02/202407:00GlobeNewswire Inc.PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care ConferenceNASDAQ:PMVPPMV Pharmaceuticals Inc
24/01/202408:01Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PMVPPMV Pharmaceuticals Inc
18/01/202415:01GlobeNewswire Inc.PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash RunwayNASDAQ:PMVPPMV Pharmaceuticals Inc
11/01/202415:18Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PMVPPMV Pharmaceuticals Inc
05/01/202415:01GlobeNewswire Inc.PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage DevelopmentNASDAQ:PMVPPMV Pharmaceuticals Inc
09/11/202307:00GlobeNewswire Inc.PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate HighlightsNASDAQ:PMVPPMV Pharmaceuticals Inc
12/10/202311:30GlobeNewswire Inc.PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C MutationNASDAQ:PMVPPMV Pharmaceuticals Inc
11/10/202311:00GlobeNewswire Inc.PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL WebinarNASDAQ:PMVPPMV Pharmaceuticals Inc
20/09/202315:05GlobeNewswire Inc.PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsNASDAQ:PMVPPMV Pharmaceuticals Inc
09/08/202307:00GlobeNewswire Inc.PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate HighlightsNASDAQ:PMVPPMV Pharmaceuticals Inc
12/06/202316:56Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PMVPPMV Pharmaceuticals Inc
09/06/202307:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PMVPPMV Pharmaceuticals Inc
06/06/202315:01GlobeNewswire Inc.PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare ConferenceNASDAQ:PMVPPMV Pharmaceuticals Inc
10/05/202307:00GlobeNewswire Inc.PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate HighlightsNASDAQ:PMVPPMV Pharmaceuticals Inc
01/05/202305:20Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:PMVPPMV Pharmaceuticals Inc
28/04/202307:05Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:PMVPPMV Pharmaceuticals Inc
28/04/202307:03Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:PMVPPMV Pharmaceuticals Inc
28/04/202307:02Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:PMVPPMV Pharmaceuticals Inc
01/03/202307:06Edgar (US Regulatory)Annual Report (10-k)NASDAQ:PMVPPMV Pharmaceuticals Inc
01/03/202307:00GlobeNewswire Inc.PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate HighlightsNASDAQ:PMVPPMV Pharmaceuticals Inc
01/03/202306:03Edgar (US Regulatory)Post-effective Amendment to an Automatic Shelf Registration of Form S-3asr or Form F-3asr (posasr)NASDAQ:PMVPPMV Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:PMVP

Su Consulta Reciente

Delayed Upgrade Clock